Trial Profile

A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camoteskimab (Primary)
Indications Multiple myeloma; Plasmacytoma
Focus Adverse reactions; Proof of concept
Sponsors Avalo Therapeutics

Most Recent Events

03 May 2022 Status changed from discontinued to completed.
06 Jan 2022 According to an Avalo Therapeutics media release, the company is discontinuing multiple myeloma program because no efficacy signal was seen in the high dose cohort or expansion phase.
06 Jan 2022 Status changed from recruiting to discontinued, according to an Avalo Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com